New lozenges aim to shrink tumors before cancer surgery
NCT ID NCT05312710
Summary
This study is testing if a new lozenge called APG-157 can safely shrink head and neck tumors before patients start their main cancer treatment, like surgery or radiation. Researchers want to see if reducing the tumor size first leads to better outcomes. The study involves 24 newly diagnosed patients who will dissolve the lozenges in their mouth three times a day for four to six weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
VAGLAHS, West Los Angeles
Los Angeles, California, 90073, United States
Conditions
Explore the condition pages connected to this study.